umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review
Show others and affiliations
2019 (English)In: European Urology Oncology, ISSN 2588-9311, Vol. 2, no 2, p. 141-149Article, review/survey (Refereed) Published
Abstract [en]

Context: The benefit of surgical metastasectomy (SM) for patients with metastatic renal cell carcinoma (mRCC) remains controversial because of the lack of high-level evidence on the role of SM in terms of survival benefit in the era of systemic therapy.

Objective: To perform a systematic review of the literature on the role of SM in the treatment of mRCC and discuss key issues in the SM decision-making process.

Evidence acquisition: A systematic search of the Embase and Medline databases was carried out and a systematic review of the role of SM in mRCC was performed. A total of 56 studies were finally included in the evidence synthesis.

Evidence synthesis: All the studies included were retrospective and mostly non-comparative. Median overall survival (OS) ranged from 36 to 142 mo for those undergoing SM, compared to 8-27 mo for no SM. SM was associated with a lower risk of all-cause mortality compared to no SM (pooled adjusted hazard ratio 2.37, 95% confidence interval 2.03-2.87; p < 0.001). Morbidity and mortality were similar for SM and primary tumor surgery. The most important prognostic factor for OS was complete resection of metastases. Other prognostic factors included disease free-survival from nephrectomy, primary tumor features (T stage >= 3, high grade, sarcomatoid features, and pathological nodal status), the number of metastases, and performance status. Lung metastasectomy seemed to show the best survival benefit.

Conclusions: Although no randomized clinical data are available, published studies support the role of SM in selected patients in the modern era. Complete SM allows sustained survival free of systemic treatment. Integration of SM and systemic therapy in a multimodal approach remains a valid option for some patients.

Patient summary: Surgical resection of metastases originating from renal cell carcinoma may play a role in prolonging survival and avoiding systemic therapy when complete resection is achievable. This strategy is an option for selected patients with a limited number of metastases who still have good general health status.

Place, publisher, year, edition, pages
Elsevier, 2019. Vol. 2, no 2, p. 141-149
Keywords [en]
Renal cell carcinoma, Metastases, Treatment, Surgery, Metastasectomy
National Category
Urology and Nephrology Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-161868DOI: 10.1016/j.euo.2018.08.028ISI: 000474610700004PubMedID: 31017089OAI: oai:DiVA.org:umu-161868DiVA, id: diva2:1340847
Available from: 2019-08-06 Created: 2019-08-06 Last updated: 2019-08-06Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Ljungberg, Börje

Search in DiVA

By author/editor
Capitanio, UmbertoLjungberg, Börje
By organisation
Urology and Andrology
Urology and NephrologyCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 8 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf